Navigation Links
Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
Date:5/4/2009

ore efficient and frequent interactions. These changes build on Amylin's scientific strength, and leverage Lilly's expertise and reach with primary care prescribers, so that we are well positioned to address the information needs of the complex diabetes market," said Daniel M. Bradbury, president and chief executive officer at Amylin Pharmaceuticals. "Today's actions are in line with our stated goal of achieving positive operating cash flow by the end of 2010, while continuing to position the company to increase sales of BYETTA and SYMLIN and bring exenatide once weekly to market as quickly as possible."

Mr. Bradbury continued, "We appreciate the significant contributions of field sales employees who will be affected by today's announcement and are grateful for their efforts and dedication to Amylin's mission."

The sales force changes will result in an annualized benefit of approximately $45 million in GAAP operating results in 2010, and a partial year benefit of approximately $20 million in 2009, which includes reductions in field sales staff and expenses, partially offset by additional cost-sharing for Lilly's primary care sales efforts. As a result of these expense reductions, which are primarily cash expenses, the Company estimates that total GAAP operating expenses for 2009 will now be at the lower end of the previously stated guidance range of $600 million to $625 million, and GAAP operating loss will also be at the lower end of the previously stated guidance range of $175 million to $200 million. This guidance for GAAP operating loss excludes a restructuring charge, estimated to be approximately $13 to $15 million, which the Company will record in the second quarter, consisting of primarily severance and other employee-related costs.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commerciali
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Md. , Aug. 19, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today that its novel ... at the 54 th Interscience Conference on ... Washington D.C. ...
(Date:8/18/2014)... A new therapy developed by researchers at the ... Medicine and Columbia University Medical Center (CUMC) may ... disease treatment. , The researchers demonstrated in ... could selectively inhibit blood vessel re-narrowing and simultaneously ... a balloon catheter to open narrowed or blocked ...
(Date:8/18/2014)... and data storage may someday run on ... to read and write digital information, outperforming ... But ferroelectrics must first overcome a few ... of "forgetting" stored data. , Now, ... Brookhaven National Laboratory have discovered nanoscale asymmetries ...
(Date:8/18/2014)... 18, 2014 TNI BioTech, Inc. (OTC-BB: TNIB) ... manufacturing and marketing of innovative therapies for autoimmune diseases ... providing a second notice of TNI BioTech,s annual meeting ... announcement, Noreen Griffin , founder and CEO of ... your participation in the Annual Meeting. On behalf of ...
Breaking Biology Technology:Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4
... (Nasdaq:,AWRE), a leading supplier of broadband technology and biometrics ... an extension to,the program originally authorized on August 28, ... up to $5 million worth of shares of,the Company,s ... until December,31, 2009 at prevailing market prices. The Board ...
... Net Revenues, $0.10 Net Income Per Share, SAN ... VNUS ), a leading provider of medical devices,for ... its,financial results for the third quarter ended September 30, ... 2008 increased 32% to $23.1,million compared with $17.5 million ...
... Transgenomic, Inc. (OTC,Bulletin Board: TBIO) today announced financial results ... results are presented in,the tables that follow., Third ... $5.4 million during the third,quarter of 2008, compared to ... from continuing operations was $2.9 million or 54,percent during ...
Cached Biology Technology:Aware, Inc. Announces Extension of Stock Repurchase Plan 2VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 2VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 3VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 4VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 5VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 6VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 7VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 8VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 9VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 10Transgenomic, Inc. Reports Third Quarter 2008 Results 2Transgenomic, Inc. Reports Third Quarter 2008 Results 3Transgenomic, Inc. Reports Third Quarter 2008 Results 4Transgenomic, Inc. Reports Third Quarter 2008 Results 5Transgenomic, Inc. Reports Third Quarter 2008 Results 6Transgenomic, Inc. Reports Third Quarter 2008 Results 7
(Date:8/19/2014)... Daylight was breaking over the central Pacific and ... about a dozen scientists strategized for the day ahead. ... to collect water samples around the southern Line Islands, ... gizmos and delicate machinery strewn throughout the 158-foot research ... research group to bring a DNA sequencer out into ...
(Date:8/18/2014)... , August 19, 2014 ... biometric authentication in smart devices  Trustonic, ... for smart devices, and Fingerprint Cards AB (FPC) ... of FIDO Ready™ secure biometric authentication on connected ... touch fingerprint sensors (FPC1020, FPC1021 and FPC1150) and ...
(Date:8/18/2014)... species native to a major Arizona watershed may lose ... as surface water flow is reduced by the effects ... these fish species, found in the Verde River Basin, ... easy access to various resources throughout the river and ... (Rhinichthys osculus), roundtail chub (Gila robusta) and Sonora sucker ...
Breaking Biology News(10 mins):Sequencing at sea 2Sequencing at sea 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 2Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 4Climate change will threaten fish by drying out Southwest US streams, study predicts 2Climate change will threaten fish by drying out Southwest US streams, study predicts 3
... , RIDGE, N.Y., Oct. 21 What,s the cost ... preventing accidental death resulting from prescription medication abuse, there,s ... be unaware that the lock-boxes they,ve installed are not ... drugs. That,s why MEDNET(TM), a national leader in premium-quality ...
... CHAPEL HILL Scientists at the University of ... the University of California, San Francisco have developed and ... for existing drugs. The researchers developed a computational ... known drugs are to the naturally occurring binding partners ...
... 4, 2009) For more than 25 years, all ... Strombus gigas ) have been unsuccessfuluntil now. For the ... beaded (nucleated) and non-beaded cultured pearls from the queen ... University,s Harbor Branch Oceanographic Institute (HBOI). With less than ...
Cached Biology News:MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Study points to new uses, unexpected side effects of already existing drugs 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Human RELT/TNFRSF19L MAb (Clone 238104)...
homeo box D3, mRNA...
Human TSLP MAb (Clone 258136)...
Biology Products: